A diversified global healthcare leader is about to shake up the diagnostic market. On 19 November 2025, news broke that Abbott Laboratories is close to sealing a deal to acquire Exact Sciences. This could be one of the 'very good opportunities out there' that Abbott's CEO Robert Ford referred to during the quarterly earnings presentation.
Abbott's acquisition target is a molecular diagnostics company specializing in the early detection and prevention of various cancers. The deal is still pending, although Exact Sciences can supercharge its Diagnostics division and potentially be the next growth driver.
